Free tool
FAERS Monitor: Nucynta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022304 or its brand name (Nucynta, Tapentadol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
31,637
Serious
29,261
92% of reports
Hospitalization
4,257
Death reported
20,703
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death11,609
- toxicity to various agents9,935
- overdose5,852
- drug abuse1,540
- drug dependence1,058
- drug withdrawal syndrome neonatal928
- drug ineffective799
- accidental overdose721
- nausea649
- pain637
- fatigue401
- intentional product misuse388
- drug interaction382
- dizziness357
- somnolence341
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 98 |
| 2010 | 155 |
| 2011 | 339 |
| 2012 | 306 |
| 2013 | 294 |
| 2014 | 299 |
| 2015 | 754 |
| 2016 | 885 |
| 2017 | 2,381 |
| 2018 | 21,519 |
| 2019 | 766 |
| 2020 | 647 |
| 2021 | 633 |
| 2022 | 548 |
| 2023 | 461 |
| 2024 | 621 |
| 2025 | 461 |
| 2026 | 468 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,522 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug withdrawal syndrome neonatalSignal | 928 | 44.4 | 41.6 | 36,876 |
| toxicity to various agentsSignal | 9,935 | 41.6 | 40.9 | 373,012 |
| overdoseSignal | 5,852 | 18.5 | 18.1 | 95,268 |
| accidental overdoseSignal | 721 | 13.3 | 12.4 | 8,075 |
| drug abuseSignal | 1,540 | 12.5 | 11.9 | 16,063 |
| deathSignal | 11,609 | 9.1 | 8.9 | 85,703 |
| drug dependenceSignal | 1,058 | 4.4 | 4.1 | 2,776 |
| intentional product misuseSignal | 388 | 3.0 | 2.7 | 500 |
| drug interaction | 382 | 1.6 | 1.5 | 86 |
| somnolence | 341 | 1.1 | 1.0 | 5 |
| pain | 637 | 0.7 | 0.6 | 92 |
| nausea | 649 | 0.5 | 0.5 | 256 |
| dizziness | 357 | 0.5 | 0.4 | 211 |
| drug ineffective | 799 | 0.4 | 0.4 | 754 |
| fatigue | 401 | 0.3 | 0.3 | 526 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.